1. Home
  2. DMRC vs SGMT Comparison

DMRC vs SGMT Comparison

Compare DMRC & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digimarc Corporation

DMRC

Digimarc Corporation

HOLD

Current Price

$9.48

Market Cap

170.6M

Sector

Technology

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$6.71

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
DMRC
SGMT
Founded
2008
2006
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
170.6M
169.4M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
DMRC
SGMT
Price
$9.48
$6.71
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
8
Target Price
$10.00
$26.13
AVG Volume (30 Days)
276.6K
783.7K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
18.58
N/A
EPS
N/A
N/A
Revenue
$25,213,000.00
$2,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
15.69
N/A
52 Week Low
$4.07
$4.50
52 Week High
$17.47
$11.41

Technical Indicators

Market Signals
Indicator
DMRC
SGMT
Relative Strength Index (RSI) 38.41 49.26
Support Level $9.52 $6.27
Resistance Level $10.31 $7.20
Average True Range (ATR) 1.26 0.33
MACD -0.68 -0.03
Stochastic Oscillator 3.78 41.88

Price Performance

Historical Comparison
DMRC
SGMT

About DMRC Digimarc Corporation

Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: